Currency in USD
| Earnings estimate | Current qtr. (Mar 2024) | Next qtr. (Jun 2024) | Current year (2024) | Next year (2025) |
|---|
| No. of analysts | 4 | 4 | 3 | 3 |
| Avg. Estimate | 0.17 | 0.27 | 0.41 | 1.15 |
| Low estimate | 0.14 | 0.18 | 0.34 | 0.9 |
| High estimate | 0.18 | 0.33 | 0.46 | 1.3 |
| Year ago EPS | 0.44 | -0.06 | 0.26 | 0.41 |
| Revenue estimate | Current qtr. (Mar 2024) | Next qtr. (Jun 2024) | Current year (2024) | Next year (2025) |
|---|
| No. of analysts | 4 | 4 | 4 | 3 |
| Avg. Estimate | 98.5M | 137.11M | 492.4M | 598.33M |
| Low estimate | 90.9M | 132.33M | 482.7M | 570M |
| High estimate | 105M | 145M | 506.3M | 633.7M |
| Year ago sales | N/A | 104.7M | 419.8M | 492.4M |
| Sales growth (year/est) | N/A | 31.00% | 17.30% | 21.50% |
| Earnings history | 30/03/2023 | 29/06/2023 | 29/09/2023 | 30/12/2023 |
|---|
| Est. EPS | -0.03 | 0.05 | 0.06 | 0.09 |
| Actual EPS | 0.44 | -0.06 | -0.07 | 0.02 |
| Difference | 0.47 | -0.11 | -0.13 | -0.07 |
| Surprise % | 1,566.70% | -220.00% | -216.70% | -77.80% |
| EPS trend | Current qtr. (Mar 2024) | Next qtr. (Jun 2024) | Current year (2024) | Next year (2025) |
|---|
| Current estimate | 0.17 | 0.27 | 0.41 | 1.15 |
| 7 days ago | 0.17 | 0.27 | 0.41 | 1.15 |
| 30 days ago | 0.17 | 0.29 | 0.43 | 1.15 |
| 60 days ago | 0.15 | 0.29 | 0.43 | 1.03 |
| 90 days ago | 0.17 | 0.29 | 0.56 | 1.04 |
| EPS revisions | Current qtr. (Mar 2024) | Next qtr. (Jun 2024) | Current year (2024) | Next year (2025) |
|---|
| Up last 7 days | N/A | N/A | N/A | N/A |
| Up last 30 days | N/A | N/A | N/A | N/A |
| Down last 7 days | N/A | N/A | N/A | N/A |
| Down last 30 days | N/A | N/A | N/A | N/A |
| Growth estimates | BIOX | Industry | Sector(s) | S&P 500 |
|---|
| Current qtr. | -61.40% | N/A | N/A | N/A |
| Next qtr. | 550.00% | N/A | N/A | N/A |
| Current year | 57.70% | N/A | N/A | N/A |
| Next year | 180.50% | N/A | N/A | N/A |
| Next 5 years (per annum) | N/A | N/A | N/A | N/A |
| Past 5 years (per annum) | N/A | N/A | N/A | N/A |
